Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May; 163(5):768-776.e2.

View in: PubMed

subject areas

Adenosine Monophosphate
Adult
Aged
Angioplasty, Balloon, Coronary
Coronary Angiography
Coronary Artery Disease
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Infusions, Intravenous
Male
Middle Aged
Myocardial Infarction
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Risk Assessment
Survival Analysis
Ticlopidine
Treatment Outcome

authors with profiles

Robert Harrington